Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
July 20, 2023 12:00 ET
|
CDA Foundation
LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq:...
Hepatitis B Vaccine Market Size To Surpass USD 12.36 Billion By 2030, exhibiting A CAGR Of 5.7%
July 17, 2023 07:06 ET
|
Fortune Business Insights
Pune, India, July 17, 2023 (GLOBE NEWSWIRE) -- According to Fortune Business Insights, the global Hepatitis B Vaccine Market size was valued at USD 7.94 billion in 2022 and is projected to grow from...
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
June 21, 2023 09:03 ET
|
Vaccitech plc
Meaningful, durable reductions of HBsAg were seen, both in participants who received VTP-300 alone and in combination with a low-dose PD-1 inhibitorTwo patients developed a non-detectable HBsAg level,...
Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023
June 21, 2023 08:00 ET
|
Assembly Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral...
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
June 07, 2023 08:00 ET
|
Assembly Biosciences, Inc.
-- International Herpesvirus Workshop will feature oral and poster presentations of preclinical data from ABI-5366, Assembly Bio’s first herpesvirus development candidate -- -- Five posters accepted...
HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B
May 09, 2023 07:01 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, May 09, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update
April 18, 2023 08:00 ET
|
Assembly Biosciences, Inc.
Phase 1a clinical data for remaining 200 mg multiple dose cohort for ABI-4334 continue to demonstrate encouraging clinical profile with strong projected activity against both viral replication and...
Hepatitis B Vaccine Market Is Expected To Reach around USD 10.62 Billion by 2030, Grow at a CAGR Of 4.5% during Forecast Period 2023 To 2030 | Data By Contrive Datum Insights Pvt Ltd.
February 10, 2023 15:38 ET
|
Contrive Datum Insights Pvt Ltd
Farmington, Feb. 10, 2023 (GLOBE NEWSWIRE) -- The Hepatitis B Vaccine Market Size Was Valued At USD 7.53 Billion In 2021. The Market Is Projected To Grow From USD 7.80 Billion In 2022 To USD 10.62...
Hepatitis B Vaccine Market Size Worth USD 10.62 billion by 2029 | Report by Fortune Business Insight
January 10, 2023 06:55 ET
|
Fortune Business Insights
Pune, India, Jan. 10, 2023 (GLOBE NEWSWIRE) -- The global hepatitis B vaccine market size was USD 7.53 billion in 2021. The market is projected to grow from USD 7.80 billion in 2022 to USD 10.62...
HOOKIPA Pharma Achieves $5 Million Milestone Payment from Gilead Sciences for Progress in the Development of Hepatitis B Vaccine
January 04, 2023 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus...